36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by -14.5 ± 26.1/-9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and -8.0 ± 24.5/-5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns.

Authors

Institutions

Publication Details

Journal
Hypertension Research
Published
2024-09-27
DOI
https://doi.org/10.1038/s41440-024-01854-w
Citations
13
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
5.23

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Lisa Thackeray, Felix Mahfoud, Maureen McGuire, Roland Erich Schmieder et al.
13 citations
Hypertension Research
Blood Pressure and Hypertension Studies
5.23
article

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Lisa Thackeray, Felix Mahfoud, Maureen McGuire, Roland Erich Schmieder, Jan Basile, Ajay Jayant Kirtane, Manish Saxena, Lisa Claude, Michael J. Bloch, Joost Daemen, Michel Azizi
article en
13 citations

Abstract

Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by -14.5 ± 26.1/-9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and -8.0 ± 24.5/-5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns.

Hypertension ResearchVol. 47(12)
Northwestern University (US), University of North Carolina at Chapel Hill (US), University of Geneva (CH), Deborah Heart and Lung Center (US), Cedars-Sinai Medical Center (US), Brigham and Women's Hospital (US), Northwell Health (US), St. Vincent's Birmingham (US), Cliniques Universitaires Saint-Luc (BE), Munson Medical Center (US), Cleveland Clinic (US), Hackensack University Medical Center (US), Nottingham University Hospitals NHS Trust (GB), NewYork–Presbyterian Hospital (US), University of Nevada, Reno (US), Emory University (US), Medical University of South Carolina (US), Imperial College Healthcare NHS Trust (GB), Inserm (FR), University of Freiburg (DE), Queen Mary University of London (GB), University of Basel (CH), Southern Illinois University School of Medicine (US), Université Paris Cité (FR), University of Utah (US), Barts Health NHS Trust (GB), University Hospitals of Cleveland (US), Royal Devon & Exeter NHS Foundation Trust (GB), Columbia University Irving Medical Center (US), Ochsner Medical Center (US), Sutter Medical Center (US), Royal Bournemouth Hospital (GB), Maastricht University Medical Centre (NL), Sparrow Hospital (US), Dorset County Hospital NHS Foundation Trust (GB), University Hospital of Wales (GB), New York Hospital Queens (US), Hammersmith Hospital (GB), Freeman Hospital (GB), Erasmus MC (NL), Bridgeport Hospital (US), Stamford Hospital (US), Conquest Hospital (GB), University Hospital of Basel (CH), University Hospital Galway (IE), National Alliance on Mental Illness (US), University Medical Center Utrecht (NL), Centre Hospitalier Universitaire de Lille (FR), University of Alabama at Birmingham (US), NYU Langone Health (US), Massachusetts General Hospital (US), Universitätsklinikum Erlangen (DE), Clinical Research Institute (US), Düsseldorf University Hospital (DE), Hôpital de la Croix-Rousse (FR), Noordwest Ziekenhuisgroep (NL), Städtisches Klinikum Karlsruhe (DE), Swedish Medical Center (US), Central Baptist Hospital (US), Assistance Publique – Hôpitaux de Paris (FR), Clinical Investigation Center Plurithematic Tours (FR), Franciscan Health Indianapolis (US), Hôpital Européen Georges-Pompidou (FR), Stony Brook Medicine (US), WakeMed (US), Hôpital Européen (FR), Hôpital Saint-André (FR), Heart Hospital Baylor Plano (US), Essex Cardiothoracic Centre (GB), Leipzig Heart Institute (DE), Kent and Canterbury Hospital (GB), Renown Regional Medical Center (US), Palo Alto Institute (US), Katholisches Klinikum Koblenz (DE), Technical University of Applied Sciences Lübeck (DE), Penn Center for AIDS Research (US), Basildon Hospital (GB), Paris Cardiovascular Research Center (FR), Ralph H. Johnson VA Medical Center (US), The Cardiac and Vascular Institute (US), Minneapolis Heart Institute Foundation (US), University of Pittsburgh Medical Center (US), Institute of Cardiology (PL), East Sussex Healthcare NHS Trust (GB), Saint Luke's Hospital (US), Klinikum Konstanz (DE), Clinique Pasteur (FR), Hôpital Civil de Charleroi (BE), University of Pennsylvania Health System (US), Cardiovascular Research Foundation (US), San Diego Cardiac Center (US), Ziekenhuis Oost-Limburg (BE), Universitäres Zentrum für Zahnmedizin Basel (CH), William Harvey Research Institute (GB), Centre Hospitalier Universitaire de Saint-Pierre (BE), Queen Elizabeth University Hospital (GB), North Mississippi Medical Center (US), University Hospitals Dorset NHS Foundation Trust, Heinrich Heine University Düsseldorf (DE), Massachusetts Institute of Technology (US), Drexel University (US), University of Tennessee at Knoxville (US), Gdańsk Medical University (PL), University of Pennsylvania (US), MedStar Health (US), Vanderbilt University Medical Center (US), Erasmus University Rotterdam (NL), Saarland University (DE), University of Colorado Denver (US), Philadelphia University (US), University of Lübeck (DE), University of Memphis (US)
Amgen, Sanofi, Alnylam Pharmaceuticals, Boston Scientific Corporation, Regeneron Pharmaceuticals, ReCor Medical, Abiomed, Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, Vifor Pharma, Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung., Servier, Idorsia Pharmaceuticals, MicroPort, Esperion Therapeutics, Abbott Vascular, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 4%
Blood Pressure and Hypertension Studies
5.23
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.